Posted by Michael Wonder on 21 Feb 2019
The fighter, the saint, and the odd man out: the executives who will defend pharma before Congress
21 February 2019 - One’s a college dropout. One’s a self-proclaimed street fighter. And one survived a presidential tweetstorm.
Meet pharma’s new Gang of Seven, a disparate group of executives about to face congressional questions on what they have in common: Their companies sell drugs, and drugs keep getting more expensive.
On Tuesday, the Senate Finance Committee will poke, prod, and pry the leaders of Merck, Pfizer, AstraZeneca, Johnson & Johnson, AbbVie, Sanofi, and Bristol-Myers Squibb. It’s a televised crucible that arrives amid bipartisan furore over the cost of medicine. Just how those seven executives defend themselves could have sweeping implications for how Washington deals with drug pricing.
